Mesirow Financial Investment Management Inc. Makes New $223,000 Investment in Surmodics, Inc. (NASDAQ:SRDX)

Mesirow Financial Investment Management Inc. acquired a new stake in shares of Surmodics, Inc. (NASDAQ:SRDX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,614 shares of the company’s stock, valued at approximately $223,000. Mesirow Financial Investment Management Inc. owned 0.05% of Surmodics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Panagora Asset Management Inc. lifted its stake in shares of Surmodics by 109.8% during the 4th quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock worth $1,624,000 after purchasing an additional 23,379 shares during the period. Vanguard Group Inc. lifted its position in Surmodics by 2.4% during the third quarter. Vanguard Group Inc. now owns 846,164 shares of the company’s stock worth $27,153,000 after buying an additional 19,635 shares during the period. Quadrature Capital Ltd acquired a new stake in Surmodics in the 4th quarter worth about $504,000. Summit Global Investments acquired a new stake in Surmodics in the 4th quarter worth about $360,000. Finally, US Bancorp DE grew its holdings in Surmodics by 61.9% in the 4th quarter. US Bancorp DE now owns 16,190 shares of the company’s stock valued at $589,000 after buying an additional 6,193 shares during the period. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Stock Up 0.0 %

Shares of NASDAQ:SRDX traded up $0.01 during midday trading on Wednesday, hitting $41.98. 142,547 shares of the company’s stock traded hands, compared to its average volume of 162,966. Surmodics, Inc. has a twelve month low of $25.17 and a twelve month high of $42.36. The company has a market cap of $598.63 million, a PE ratio of 44.18 and a beta of 1.18. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.59 and a current ratio of 4.39. The firm’s fifty day moving average price is $37.02 and its two-hundred day moving average price is $33.47.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Wednesday, May 1st. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.43. The company had revenue of $31.96 million during the quarter, compared to the consensus estimate of $28.79 million. Surmodics had a return on equity of 13.30% and a net margin of 9.44%. During the same quarter in the prior year, the business earned ($0.40) earnings per share. On average, equities research analysts anticipate that Surmodics, Inc. will post -0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SRDX shares. Barrington Research reiterated a “market perform” rating on shares of Surmodics in a report on Thursday, May 30th. StockNews.com assumed coverage on shares of Surmodics in a report on Tuesday. They issued a “hold” rating on the stock. Lake Street Capital reissued a “hold” rating and set a $43.00 price objective on shares of Surmodics in a research note on Wednesday, May 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research report on Wednesday, May 29th. Finally, Sidoti reiterated a “neutral” rating and issued a $43.00 target price on shares of Surmodics in a report on Wednesday, May 29th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $50.00.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).